319 related articles for article (PubMed ID: 33011863)
1. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
Syrykh C; Ysebaert L; Péricart S; Evrard SM; Meggetto F; Kanoun S; Brousset P; Laurent C
Virchows Arch; 2021 Apr; 478(4):779-783. PubMed ID: 33011863
[TBL] [Abstract][Full Text] [Related]
2. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
3. Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.
Molica S; Gianfelici V; Levato L
Expert Opin Emerg Drugs; 2020 Mar; 25(1):25-35. PubMed ID: 31996046
[No Abstract] [Full Text] [Related]
4. Distinct Clinicopathologic Features and Possible Pathogenesis of Localized ALK-positive Histiocytosis of the Breast.
Osako T; Kurisaki-Arakawa A; Dobashi A; Togashi Y; Baba S; Shiozawa S; Ishigame H; Ishige H; Ohno S; Ishikawa Y; Takeuchi K
Am J Surg Pathol; 2022 Mar; 46(3):344-352. PubMed ID: 34482333
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
[No Abstract] [Full Text] [Related]
6. Expanding the Phenotype of ALK-positive Histiocytosis: A Report of 2 Cases.
Huang H; Gheorghe G; North PE; Suchi M
Pediatr Dev Pathol; 2018; 21(5):449-455. PubMed ID: 29224419
[TBL] [Abstract][Full Text] [Related]
7. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
[TBL] [Abstract][Full Text] [Related]
8. ALK-rearranged histiocytosis: Report of two cases with involvement of the central nervous system.
Rossi S; Gessi M; Barresi S; Tamburrini G; Giovannoni I; Ruggiero A; Colafati GS; Frassanito P; Carboni A; Alexandre A; Cacchione A; Trombatore P; Diomedi-Camassei F; Gaspari S; Gianno F; Marras CE; Cecinati V; Carai A; Mastronuzzi A; Alaggio R
Neuropathol Appl Neurobiol; 2021 Oct; 47(6):878-881. PubMed ID: 34048085
[TBL] [Abstract][Full Text] [Related]
9. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
10. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
[TBL] [Abstract][Full Text] [Related]
11. Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.
Martín-Moro F; García-Cosío M; Marquet-Palomanes J; López-Gutiérrez M; Pian-Arias H; López-Jiménez FJ
Ann Hematol; 2022 Jan; 101(1):213-215. PubMed ID: 33423076
[No Abstract] [Full Text] [Related]
12. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
13. Ibrutinib-Induced Skin Rash.
Kirar S; Gogia A; Gupta R; Mallick S
Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
[No Abstract] [Full Text] [Related]
14. Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
Wimalachandra M; Basu TN; Salisbury J; Attard N; Calonje E; Patten PEM
Clin Exp Dermatol; 2021 Dec; 46(8):1569-1571. PubMed ID: 34028865
[No Abstract] [Full Text] [Related]
15. Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.
Gentile M; Morabito F; Del Poeta G; Mauro FR; Reda G; Sportoletti P; Laurenti L; Coscia M; Herishanu Y; Recchia AG; Varettoni M; Murru R; Chiarenza A; Condoluci A; Moia R; Pietrasanta D; Loseto G; Consoli U; Scortechini I; Rossi FM; Zucchetto A; Fraticelli V; Vigna E; Botta C; Tripepi G; Arrigo G; Rago A; Angeletti I; Biagi A; Del Giudice I; Bomben R; Rigolin GM; Rossi D; Di Raimondo F; Gaidano G; Polliack A; Cuneo A; Foà R; Gattei V
Leukemia; 2021 Jan; 35(1):235-238. PubMed ID: 32286543
[No Abstract] [Full Text] [Related]
16. Concomitant autoimmune hemolytic anemia and pure red cell aplasia in a patient with chronic lymphocytic leukemia successfully treated with ibrutinib.
Krečak I; Čengić M; Skorić I; Nakić M; Gverić-Krečak V
Ann Hematol; 2021 Nov; 100(11):2861-2862. PubMed ID: 34109444
[No Abstract] [Full Text] [Related]
17. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology.
Kashima J; Yoshida M; Jimbo K; Izutsu K; Ushiku T; Yonemori K; Yoshida A
Am J Surg Pathol; 2021 Mar; 45(3):347-355. PubMed ID: 32826530
[TBL] [Abstract][Full Text] [Related]
18. Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.
Molica S; Baumann T; Giannarelli D
Eur J Haematol; 2021 Mar; 106(3):425-427. PubMed ID: 33190324
[No Abstract] [Full Text] [Related]
19. What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
Bravaccini S; Martinelli G; Cerchione C
Cell Transplant; 2020; 29():963689720950209. PubMed ID: 32907382
[TBL] [Abstract][Full Text] [Related]
20. Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia.
Tahir F; Sy J; Reddel S; Trotman J
Leuk Lymphoma; 2022 Jun; 63(6):1464-1468. PubMed ID: 35037559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
